DETROIT, Aug. 21, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE) is pleased to report today the results of testing of its proprietary Nanotechnology Immune Stimulant (NIS) which prevents the propagations of infections made by Vibrio Parahaemolyticus, a bacteria that cause disease in cultured shrimp.
Nano Lab's innovative solution is a Nanotech Immune Stimulant (NIS), which modulates the response of the immune system in shrimp. Tests conducted in partnership with CIBNOR, Bioassay Project No 960-0, shows the NIS increases the number of immune cells, and a considerable reduction of the proliferation rate of the bacteria.
Nano Labs and CIBNOR are pleased to report the following first round of results from the commercial pilot program.
The NIS was incorporated in the shrimp feed at various concentrations where the shrimps were fed daily at libitum up to 30 days. The daily administration of the NIS ranged in concentrations of 0 μg NIS / gram of feed (for the control tank) up to 500 μg NIS / gram of feed across six (6) treatment tanks. The treatment tanks contained three hundred (300) shrimp per tank and the mortality rate was recorded daily on the total 1,800 shrimp infected with the Parahaemolyticus Vibrio.
The percentage of shrimp survival after direct infection was 15% and 20% at 500 ug NIS / gram of feed. Further, the trials showed there is no health risk to the shrimp and the product does not affect shrimp larval development or survival.
"The laboratory preliminary numbers show promising results for shrimp at the levels tested and these dosages are effective against Parahaemolyticus Vibrio. The NIS has remarkable antibacterial activity towards the bacteria when it is incorporated in the culture media at concentrations over 10%," states Dr. Victor Castano, Chief Innovations Officer at Nano Labs. "Further tests are required that compare the effectiveness of our nanotech immune stimulant with other products available on the market as a antibacterial cocktail, as Parahaemolyticus Vibrio affects 30% of worldwide shrimp production. We are continuing to develop and test the product with the goal of achieving a 100% survival rate."
The shrimp aquaculture industry
Aquaculture is the fastest growing food production sector in the world and has been established as an important source of protein to meet food demand worldwide because the natural resources are now overexploited. But at present, the biggest problem facing the aquaculture industry worldwide, are the diseases caused by various biological and non-biological agents. Among the groups of microorganisms that cause serious losses in shrimp farming, the best known are bacteria due to the devastating effects they have on affected farms. Bacterial diseases are mainly due to Vibrio, which have been reported in the penaeid shrimp culture systems and implicates at least 14 species, and among them the Parahaemolyticus Vibrio is one of the most lethal. Its effects caused massive epidemics in Thailand and the Philippines in the early 90's and now it represents a worldwide problem.
Vibriosis is one of the major disease problems in aquaculture seafood and fish. Vibriosis is a bacterial disease responsible for mortality of cultured shrimp worldwide. Vibriosis is present throughout the world and in all marine crustaceans, including shrimps which are the most susceptible.
The shrimp aquaculture industry has grown at a rate of 10% per year for the last decade, producing over 4 million tons of shrimp in 2011, with an estimated total value of 15 billion USD for the global shrimp market. Shrimp exports in 2012 brought Vietnam over 2.23 USD billion despite losses of 373 million USD due to the White Spot Virus in 2010.
Despite this positive growth, the shrimp aquaculture industry faces challenges related to increasing hazards in biosecurity, production costs and overall sustainability. Infectious diseases, especially from microorganisms, are a leading problem and expansion of the industry has been greatly hindered by the presence of these diseases, which negatively affect worldwide production.
Additional Information
Companies, organizations or governments interested in requesting a copy of the Full Report, are invited to contact Mr. Bernardo Camacho Chavarria, President of Nano Labs.
Additional information on the Company's Joint Venture with CIBNOR can be found in the Company's press release of June 11, 2013 here, http://nanolabs.us/press-releases/nano-labs-announces-joint-venture-with-cibnor/.
For more information on CIBNOR, please visit www.cibnor.com.mx.
About Nano Labs
Nano Labs Corp. (CTLE) is a nanotechnology research and development company which began in October, 2012, but is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. Our Company's research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.
The Nano Labs Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16293
Forward looking statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.